Stock Traders Purchase Large Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw some unusual options trading on Monday. Stock investors bought 11,259 call options on the stock. This is an increase of 2,053% compared to the average volume of 523 call options.

Sangamo Therapeutics Price Performance

NASDAQ:SGMO traded up $0.00 on Monday, reaching $0.51. The company’s stock had a trading volume of 292,173 shares, compared to its average volume of 2,196,794. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.78. The stock has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.59.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. The business had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $8.96 million. Equities analysts expect that Sangamo Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors have recently modified their holdings of the company. Wasatch Advisors LP boosted its position in shares of Sangamo Therapeutics by 62.4% during the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after acquiring an additional 7,734,400 shares in the last quarter. Golden State Equity Partners raised its stake in Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 34,960 shares during the last quarter. Mackenzie Financial Corp raised its stake in Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 31,003 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 129,811 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Sangamo Therapeutics by 103.9% during the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 92,002 shares during the last quarter. 56.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. StockNews.com began coverage on Sangamo Therapeutics in a research note on Tuesday, February 13th. They issued a “sell” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a research note on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Sangamo Therapeutics presently has an average rating of “Hold” and an average price target of $4.93.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.